Claim a Free Sample
Get a preview with key statistics, projections, and trends for this report. Ideal for quick insights.
Send Me a SampleNeed full access?
Purchase ReportCOPD & Asthma Therapeutics Market Trends
At USD 92.30 billion in 2024, the worldwide COPD and asthma treatments market is estimated to rise at a CAGR of 9.18% from 2025 to 2030. Rising pollution levels, tobacco use, and aging populations, all aggravating chronic respiratory problems, are driving demand for bronchodilators, corticosteroids, and combination treatments far higher.Size, byProduct, 2024 - 2030{USD Billion} COPD and asthma treatments market size is estimated to rise at a CAGR of 9.18% from 2025 to 2030. request a free sample copy
Global COPD & Asthma Drugs Market Trends
Key Highlights
- North America COPD and asthma therapeutics and market held the largest revenue share, 40.1%, in 2024
- The COPD and asthma therapeutics industry in the U.S. held the largest revenue share in 2024.
- Based on drug class, the Anti-IgE and Anti-IL monoclonal antibodies segment dominated the market with a revenue share of 22.72% in 2024.
- Based on device/product, the inhalers segment accounted for the largest revenue share in 2024.
- Based on indications, the asthma segment accounted for the largest revenue share of the COPD and asthma therapeutics market in 2024.
For instance, according to the Global Initiative for Asthma (GINA), asthma affected over 262 million people globally in 2022, while the WHO reported that COPD was the third leading cause of death worldwide. In addition, a growing aging population coupled with increasing automotive and industrial exhaust gases remains the key driver for the global COPD and asthma therapeutics industry. Degrading air quality near industrial areas has led to an increased incidence of asthma. According to the European Environment Agency, air pollutant levels in 2021 significantly exceeded the levels specified by the World Health Organization's (WHO) air quality guidelines. Achieving these recommended levels could have prevented a significant number of deaths across EU Member States (EU-27), including 253,000 deaths linked to exposure to fine particulate matter (PM2.5) and 52,000 deaths caused by nitrogen dioxide (NO2) exposure. In addition, reducing short-term exposure to ozone (O₃) could have reduced 22,000 attributable deaths.
The market for COPD and asthma treatments is growing because of new technology in drug delivery devices, like smart inhalers that connect to Bluetooth and AI tools for monitoring breathing, which help patients stick to their treatment plans and allow doctors to manage patients from a distance. Companies like Propeller Health and Teva have introduced FDA-approved smart inhalers that track medication usage and transmit data to clinicians in real time.
Moreover, the growing penetration of mobile health apps and telepulmonology solutions is improving access to care, especially in underserved areas. The expansion of online pharmacies and direct-to-consumer digital platforms is also streamlining therapy access, supporting the shift toward home-based disease management. Collectively, these advancements across therapeutic classes, delivery devices, and digital tools are expected to drive sustained growth in the COPD and asthma market through 2030.
Increasing healthcare expenditure, improved access to care in developing regions, and supportive government initiatives aimed at managing chronic respiratory conditions are further enhancing market potential. The rise of universal healthcare programs in countries such as India and China is expanding access to essential inhalers and diagnostics. For instance, China's Healthy China 2030 initiative focuses on four strategic pillarsequitable access and outcomes in health and healthcare, healthcare systems transformation, technology and innovation, and environmental and climate sustainability. Equity is the foundational goal, guiding efforts to reduce barriers in healthcare systems and improve health outcomes across the country.
The COVID-19 pandemic positively impacted the COPD and asthma therapeutics industry. Initially, disruptions in healthcare access, reduced pulmonary function testing, and delayed diagnoses led to a decline in treatment rates and prescription volumes. However, as the pandemic progressed, heightened awareness of respiratory health and the increased risk of severe COVID-19 outcomes in patients with chronic lung diseases drove greater adherence to maintenance therapies. The shift toward home-based care, telemedicine, and digital health tools, such as smart inhalers and remote monitoring, supported continued treatment and patient engagement. While the market faced short-term setbacks, the pandemic ultimately reinforced the importance of proactive respiratory care, leading to long-term growth opportunities.
Report Coverage & Deliverables
The PDF report & online dashboard will help you understand
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
AI in COPD And Asthma Therapeutics Market
Artificial Intelligence (AI) is playing an increasingly transformative role in the COPD and asthma therapeutics industry by enabling more personalized, predictive, and proactive disease management. AI-powered tools can analyze large volumes of patient data to identify early warning signs of exacerbations, optimize treatment plans, and support remote monitoring, thereby improving clinical outcomes and reducing hospitalizations. For instance, FindAir, a Finland-based med-tech company, offers AsthmaAI, an advanced AI-driven solution that uses real-world data from connected inhalers to predict asthma attacks and personalize therapy recommendations. By integrating data such as inhaler use patterns, environmental factors, and individual health metrics, AsthmaAI exemplifies how AI is enhancing the effectiveness of respiratory disease management. As AI continues to integrate with smart inhalers, mobile apps, and clinical decision support systems, it is set to revolutionize how COPD and asthma are treated and monitored globally.
Market Concentration & Characteristics
The chart below illustrates the relationship between market concentration, characteristics, and participants. The x-axis represents the level of industry concentration, ranging from low to high. The y-axis represents various industry characteristics, including industry competition, the impact of regulations, the level of partnerships and collaboration activities, the degree of innovation, and regional expansion. For instance, the COPD and asthma therapeutics market is slightly fragmented, with many product & service providers entering the market. The degree of innovation, the level of partnership and collaboration activities, and the impact of regulations on the industry are high. However, the regional expansion observes moderate growth.
The degree of innovation in the industry is moderate to high. The market is experiencing significant advances in certain areas, especially in biologics, drug-device combinations, and digital health technologies, while more traditional segments like inhaled generics remain relatively mature. In September 2024, the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) as the first-ever biologic medicine for patients with chronic obstructive pulmonary disease (COPD).
Key players in the industry are engaging in a high level of partnerships and collaboration activities to enhance their capabilities, expand product portfolios, and improve competencies. In March 2024, AstraZeneca Pharma India Ltd partnered with Mankind Pharma to exclusively distribute its asthma medication, Symbicort, in India. This collaboration aims to enhance access to treatment across the country, leveraging Mankind Pharma's extensive distribution network.
The impact of regulations on the market is high. Regulatory frameworks significantly shape the COPD and asthma therapeutics market, influencing drug approval timelines, market access, pricing, and device innovation. In developed markets like the U.S., the FDA’s stringent approval process ensures safety and efficacy, particularly for complex inhalation devices and combination therapies such as ICS/LABA and triple therapies. In Europe, the EMA requires solid clinical proof for approval, especially for biologics, and has played an important role in creating rules about inhaler propellants, encouraging a move from hydrofluoroalkane (HFA)-based MDIs to more environmentally friendly inhalers.
The COPD and asthma therapeutics industry's level of regional expansion is moderate. Regional expansion has become a key growth strategy for pharmaceutical companies in the COPD and asthma therapeutics industry, significantly broadening patient access, driving revenue, and diversifying product portfolios. For instance, in July 2023, Viatris Inc. launched Breyna, an FDA-approved generic version of AstraZeneca's Symbicort inhalation aerosol, in partnership with Kindeva Drug Delivery. This aerosol is used for treating COPD and asthma. This launch provides a more affordable treatment option for patients with COPD and asthma in the United States.
Drug Class Insights
The Anti-IgE and Anti-IL monoclonal antibodies segment dominated the market with a revenue share of 22.72% in 2024. We attribute the segment's large share to its targeted and highly effective approach in managing severe and uncontrolled forms of COPD and asthma. These biologics, such as omalizumab (Anti-IgE), mepolizumab, and dupilumab (Anti-IL), are made to target important inflammation processes that worsen the disease. Furthermore, these monoclonal antibodies are particularly beneficial for patients who do not respond adequately to standard treatments, offering improved symptom control, reduced exacerbation rates, and better overall quality of life. For instance, in April 2021, the FDA approved Xolair, a biologic, to treat moderate to severe persistent allergic asthma, Chronic Idiopathic Urticaria (CIU), and nasal polyps.
The combination therapy segment is expected to grow at the fastest CAGR during the forecast period due to its superior clinical efficacy, convenience, and growing adoption in both moderate and severe disease management. In addition, the availability of several fixed-dose combination inhalers has made combination therapy more convenient for patients, further contributing to its higher adoption. For instance, in June 2022, Glenmark Pharmaceuticals Limited introduced a new fixed-dose combination drug, Indamet, in India for uncontrolled asthma. As a result of these factors, combination therapy is expected to dominate the market in the coming years.
Device/Product Insights
The inhalers segment accounted for the largest revenue share in 2024. Several factors, including their reliability, versatility, portability, and cost-effectiveness, contribute to this. Moreover, the increasing prevalence of COPD & asthma and the growing need for emergency treatment alternatives against sudden attacks have contributed to a significant market share of inhalers. The inhalers segment is expected to grow further due to the innovations in the existing products. For instance, the U.S. approved GSK Plc. and Innoviva's triple therapy inhaler, Trelegy Ellipta, in September 2020 for the treatment of asthma and COPD.
The nebulizers segment is expected to register the fastest CAGR from 2025 to 2030. One of the primary drivers is ease of use, making nebulizers particularly suitable for children, elderly patients, and severe asthmatic patients who struggle with inhaler techniques. Additionally, more people are using nebulizers at home and in emergencies because they are comfortable, can deliver larger doses for better results, and are often covered by insurance, which is expected to boost market growth. Furthermore, continuous advancements in nebulizer technology, such as portable and handheld devices, increase patient compliance and convenience. For instance, in July 2020, OMRON Corporation launched OMRON NE C106, a compressor nebulizer designed to deliver medication directly to the lungs in the form of a mist.
Indication Insights
The asthma segment accounted for the largest revenue share of the COPD and asthma therapeutics market in 2024. The dominance of the segment is attributed to the increasing prevalence of asthma among the population. According to WHO estimates, asthma affected 262 million patients globally, with inflammation and narrowing of the lungs being common. The segment has a strong research pipeline, with many candidates in late-stage or mid-stage development. Several double and triple combination inhalers for asthma are also in the last stages of development, with the objective of increasing medication adherence. For example, in May 2022, PT027 (a combination of Albuterol and Budesonide), created by AstraZeneca and Avillion working together, showed good results in Phase III clinical trials and has been accepted by the FDA as a new drug application from both companies.
The Chronic obstructive pulmonary disease (COPD) segment is expected to show lucrative growth during the forecast period. The growth of the segment is associated with the rising geriatric population, as a result of which the demand for COPD drugs is also expected to surge. Individuals aged over 65 years are at higher risk of developing COPD. The prevalence of COPD is lower than asthma; however, it leads to 5% of deaths globally. Overdiagnosis is also a factor associated with a high prevalence of COPD. The condition is more prevalent in low- and middle-income countries and has a high rate of mortality.
Technology/Software Insights
The smart inhaler with Bluetooth connectivity segment held the largest revenue share in 2024, attributed to their ability to enhance medication adherence, enable real-time monitoring, and support data-driven treatment decisions. These devices automatically track inhaler usage and transmit data to mobile apps or healthcare platforms, allowing patients and providers to manage respiratory conditions better. Further, in September 2020, Teva Pharmaceuticals launched ArmonAir Digihaler, an inhalation powder, and AirDuo Digihaler, an inhalation powder. These digital maintenance inhalers for asthma patients feature built-in sensors and Bluetooth connectivity to monitor usage and provide actionable insights. As digital health adoption grows, smart inhalers are becoming integral to personalized respiratory care, driving their widespread uptake in the market.
Distribution Channel Insights
The hospital pharmacies segment accounted for the largest revenue share in 2024. High demand for immediate and specialized treatment during acute episodes often necessitates hospitalization or emergency care. Patients with moderate to severe asthma or COPD frequently experience exacerbations that lead them to hospital settings, where rapid access to bronchodilators, corticosteroids, and biologics is critical. Furthermore, there is a significant rise in the number of hospital admissions for asthma and COPD patients. According to the Asthma and Allergy Foundation of America, asthma accounted for 94,560 discharges from hospital inpatient care and 986,453 emergency department visits in 2020.
The online pharmacies segment is expected to register the fastest CAGR from 2025 to 2030. This growth is driven by shifting consumer preferences, growing digital adoption, and the expanding reach of e-commerce in healthcare. The convenience of doorstep delivery, increased accessibility to medications, and availability of digital consultation services make online platforms particularly attractive for chronic disease patients who require regular and long-term medication management.
Regional Insights
North America's COPD and asthma therapeutics market held the largest revenue share in 2024, driven by increasing disease prevalence, an aging population, and rising healthcare expenditures. The region dominates the global market, supported by advanced healthcare infrastructure and growing adoption of innovative treatment solutions such as biologics and smart inhalers. Rising environmental pollution, especially in urban areas, continues to be a key driver of respiratory conditions, prompting demand for improved therapeutics and diagnostic tools.
U.S. COPD And Asthma Therapeutics Market Trends
The COPD and asthma therapeutics industry in the U.S. held the largest revenue share in 2024. According to the Centers for Disease Control and Prevention (CDC), asthma affects approximately 25 million people, including over 4.6 million children under 18, contributing to the market's growth in this region. Substantial R&D investments, public awareness campaigns, and government initiatives supporting COPD and asthma research further fuel the market. For instance, in 2022, the National Asthma Control Program received USD 30 million in federal funding, supporting CDC asthma programs and propelling market growth.
Europe COPD And Asthma Therapeutics Market Trends
The COPD and asthma therapeutics industry in Europe is anticipated to grow significantly over the forecast period. The primary factors driving this demand are environmental regulations and the adoption of sustainable healthcare practices. For example, in March 2024, the European Union (EU) introduced new laws to control fluorinated gases and other substances that harm the ozone layer, aiming to completely stop their use by 2050. This is expected to greatly affect the asthma and COPD treatment market in Europe by encouraging the use of low-emission inhalers. This legislation can tend to limit the adoption of metered-dose inhalers owing to their hydrofluorocarbon content; however, it can also fuel the adoption of dry-powder and soft-mist inhalers in the region.
The UK COPD and asthma therapeutics market is influenced by the National Health Service's (NHS) emphasis on cost-effective treatments and environmental sustainability. The NHS has been encouraging the use of low-carbon inhalers, and pharmaceutical companies are responding by developing inhalers with reduced environmental impact. For instance, GSK, a UK-based pharmaceutical and biotechnology company, initiated Phase III trials for a low-carbon version of its Ventolin inhaler, aiming to reduce greenhouse gas emissions by approximately 90% through the use of a next-generation propellant. This development is a significant step toward GSK's net-zero climate targets, considering that the current inhaler accounts for nearly half of the company's carbon footprint.
The COPD and asthma therapeutics market in Germany is driven by a robust healthcare system and a strong emphasis on research and development. The country's focus on early diagnosis and comprehensive disease management programs contributes to effective treatment outcomes. Moreover, Germany's commitment to environmental sustainability is driving the adoption of eco-friendly inhalers, aligning with broader EU initiatives to reduce greenhouse gas emissions from medical devices.
Asia Pacific COPD And Asthma Therapeutics Market Trends
Asia Pacific is expected to witness the fastest growth during the forecast period. The region experiences growth in the COPD and asthma therapeutics industry, driven by increasing urbanization, pollution, and smoking rates. For instance, according to the World Health Organization, 3.1 million preventable deaths are caused by tobacco in South Asia, out of 8 million deaths worldwide. The growing geriatric population and rising awareness about lung diseases are the major driving factors in this region. In Southeast Asia, asthma is reported as one of the most common non-communicable diseases and is responsible for nearly 73% of the visits to outpatient clinics. Moreover, developing healthcare infrastructure in Asia-Pacific countries, such as Indonesia, China, and India, is expected to propel the market in the coming years.
The China COPD and asthma therapeutics market is expected to witness growth over the forecast period due to the country’s significant burden of respiratory diseases. For instance, according to the World Health Organization, as of November 2023, around 100 million people in China are living with chronic obstructive pulmonary disease, which accounts for almost 25% of all global COPD cases. Further, Government initiatives, such as the national COPD screening program implemented in October 2021, aim to improve early diagnosis and treatment, contributing to the growth of the market in China.
The COPD and asthma therapeutics market in India is expected to grow significantly over the forecast period. The growing geriatric population, government initiatives supporting the country’s Health scenario, and growing strategic developments by key players in the region are contributing to the growth of the Indian asthma therapeutics and COPD market. For instance, in November 2023, Lupin launched Vilfuro-G, the fixed-dose triple combination drug for managing chronic obstructive pulmonary disease (COPD) in India.
Latin America COPD And Asthma Therapeutics Market Trends
Increasing awareness and access to healthcare, along with improved treatment availability and greater understanding of chronic respiratory conditions, are contributing to higher diagnosis and management rates across Latin America, which is driving the COPD and asthma therapeutics industry in the region. However, the region faces challenges like economic disparities and limited healthcare infrastructure in certain areas.
Middle East & Africa COPD And Asthma Therapeutics Market
Over the forecast period, we expect the COPD and asthma therapeutics industry in the Middle East & Africa to grow significantly. Urbanization and rising pollution levels drive market growth. Furthermore, we expect countries like Saudi Arabia to register the highest growth rates. However, challenges such as limited access to healthcare services and affordability issues persist, particularly in low-income regions.
| Region | 2024 Market Size (USD Billion) | 2030 Market Size (USD Billion) | CAGR (2025–2030) | Key Growth Drivers |
|---|---|---|---|---|
| North America | 34.8 | 58.8 | ~9.1% | High disease prevalence, advanced healthcare infrastructure, reimbursement support, presence of major pharma companies. |
| Europe | 26.5 | 44.9 | ~9.2% | Aging population, increasing adoption of advanced inhalation therapies, strong regulatory support for respiratory care. |
| Asia-Pacific | 21.0 | 37.0 | ~9.6% | Rising pollution, smoking rates, large patient pool, healthcare expansion in China & India, government programs. |
| Latin America | 6.3 | 10.9 | ~9.3% | Growing asthma cases in younger populations, urbanization, adoption of advanced therapies in urban hospitals. |
| Middle East & Africa | 3.7 | 6.4 | ~9.4% | Urbanization, rising awareness, gradual healthcare infrastructure improvements, government reforms. |
| Global Total | 92.3 | 156.0 | 9.18% | Pollution, tobacco use, aging populations, rising demand for bronchodilators, corticosteroids, and combination therapies. |
In 2024, the global COPD and asthma treatments market was valued at USD 92.30 billion. It is projected to expand significantly and reach nearly USD 156.0 billion by 2030, growing at a CAGR of 9.18% during the forecast period (2025–2030). This rapid expansion is fueled by rising air pollution, increased tobacco consumption, and aging populations, which collectively worsen chronic respiratory conditions, thereby driving demand for bronchodilators, corticosteroids, and combination therapies.
North America held the largest share, valued at about USD 34.8 billion in 2024, with an expected growth to USD 58.8 billion by 2030. The region benefits from a well-established healthcare infrastructure, high prevalence of asthma and COPD, favorable reimbursement policies, and the presence of leading pharmaceutical manufacturers driving innovation in inhaled therapies and biologics.
Europe followed closely, accounting for nearly USD 26.5 billion in 2024, projected to reach USD 44.9 billion by 2030. Growth in Europe is supported by rising cases of chronic respiratory diseases in aging populations, strong emphasis on early diagnosis, and increasing adoption of advanced inhalation drug delivery systems.
The Asia-Pacific region represented about USD 21.0 billion in 2024, forecasted to grow to USD 37.0 billion by 2030. This region is expected to post the fastest CAGR, driven by worsening air pollution levels in major economies like India and China, growing smoking prevalence, and improving healthcare access. Expanding awareness programs and rising government investments in respiratory disease management also contribute to growth.
In Latin America, the market size stood at approximately USD 6.3 billion in 2024 and is expected to reach USD 10.9 billion by 2030. Key drivers include an increasing burden of asthma in children and young adults, combined with the gradual adoption of advanced therapeutics across urban healthcare centers.
The Middle East and Africa market was valued at about USD 3.7 billion in 2024 and is projected to expand to USD 6.4 billion by 2030. Although this region faces limited access to advanced therapies, growing awareness, urbanization, and government healthcare reforms are contributing to steady market growth.
Key COPD And Asthma Therapeutics Company Insights
The market is highly fragmented, with many small and large players operating in this space. This leads to intense competition between smaller players to sustain their position. Strategies such as new product launches and partnerships are playing a key role in propelling the market growth.
Key COPD And Asthma Therapeutics Companies
The companies listed below are the leaders in the COPD and asthma therapeutics market. These companies collectively hold the largest market share and dictate industry trends.
- Teva Pharmaceutical Industries Ltd.
- GSK plc
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Sanofi
- Koninklijke Philips N.V.
- BD
- Covis Pharma
- Findair Sp. z o. o.
- Novartis AG
- Cipla Ltd.
- Chiesi Air
COPD And Asthma Therapeutics Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 100.06 billion |
|
Revenue forecast in 2030 |
USD 155.25 billion |
|
Growth rate |
CAGR of 9.18% from 2025 to 2030 |
|
Actual data |
2018-2024 |
|
Forecast period |
2025-2030 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Drug class, device/product, technology/software, indication, distribution channel, region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
|
Country scope |
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Norway; Denmark; Sweden; China; Japan; India; South Korea; Australia; Thailand; Brazil; Argentina; Saudi Arabia; South Africa; UAE; Kuwait |
|
Key companies profiled |
Teva Pharmaceutical Industries Ltd.; GSK plc; Merck & Co., Inc.; F. Hoffmann-La Roche Ltd; AstraZeneca; Boehringer Ingelheim International GmbH; Sanofi; Koninklijke Philips N.V.; BD; Covis Pharma; Findair Sp. z o. o.; Novartis AG; Cipla Ltd.; Chiesi Air |
|
Customization scope |
We offer free report customization, equivalent to up to 8 analysts' working days, with every purchase. Changes or additions to the scope of the country, region, and segment are possible. |
|
Pricing and purchase options |
Avail yourself of customized purchase options to meet your exact research needs. Explore purchase options |
Global COPD And Asthma Therapeutics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, MIR has segmented the global COPD and asthma therapeutics market report based on drug class, device/product, technology/software, indication, distribution channel, and region
-
Drug Class Outlook (Revenue, USD Million, 2018-2030)
-
Bronchodilators
-
Corticosteroids
-
Leukotriene Modifiers
-
Anti-IgE and Anti-IL Monoclonal Antibodies
-
Combination Therapy
-
Others
-
-
Device/Product Outlook (Revenue, USD Million, 2018-2030)
-
Inhalers
-
Dry Powder Inhalers (DPI)
-
Metered Dose Inhalers (MDI)
-
Soft Mist Inhalers (SMI)
-
-
Nebulizers
-
Jet
-
Mesh
-
Ultrasonic
-
-
Oxygen Therapy Devices
-
-
Technology/Software Outlook (Revenue, USD Million, 2018 - 2030)
-
Smart Inhalers with Bluetooth Connectivity
-
AI-based Respiratory Monitoring Platforms
-
Mobile Apps for Symptom Tracking
-
Digital Adherence and Reminder Systems
-
Telepulmonology Solutions
-
-
Indication Outlook (Revenue, USD Million, 2018 - 2030)
-
Asthma
-
COPD
-
-
Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
-
Drugstores
-
-
Regional Outlook (Revenue, USD Million, 2018 - 2030)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
China
-
Japan
-
India
-
South Korea
-
Australia
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East and Africa (MEA)
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Frequently Asked Questions
The global COPD and asthma therapeutics market size was estimated at USD 92.30 billion in 2024 and is expected to reach USD 100.06 billion in 2025.
The global COPD and asthma therapeutics market is expected to grow at a compound annual growth rate of 9.18% from 2025 to 2030 to reach USD 155.25 billion by 2030.
Anti-IgE and Anti-IL monoclonal antibodies segment dominated the market with a revenue share of 22.72% in 2024. The segment's large share is attributed to its targeted and highly effective approach in managing severe and uncontrolled forms of COPD and asthma.
Some key players operating in the COPD and asthma therapeutics market include Teva Pharmaceutical Industries Ltd., GSK plc, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Boehringer Ingelheim International GmbH, Sanofi, Koninklijke Philips N.V., BD, Covis Pharma, Findair Sp. z o. o., Novartis AG, F. Hoffmann-La Roche Ltd, Cipla Ltd., Chiesi
Key factors that are driving the market growth include the increasing prevalence of chronic respiratory conditions—exacerbated by rising pollution levels, tobacco consumption, and aging populations significantly boosting demand for these therapeutics devices and solutions.